

European Biopharmaceutical Enterprises (EBE) is the European trade association that represents biopharmaceutical companies of all sizes operating in Europe. EBE was established in 2000 as a specialised group of EFPIA and is headquartered in Brussels. EBE actively promotes a favourable economic, business, scientific and regulatory environment for biopharmaceutical in Europe and also provides a wide range of value-added services to its 65 member companies. Membership in EBE is open to all companies using biotechnology to discover, develop and bring new medicinal products to market.

EBE – European Biopharmaceutical Enterprises
 Rue du Trône 108 | 1050 Brussels | Belgium
 Tel: +32 2 6262561 | Fax: +32 2 6262566
 info@ebe-biopharma.org | www.ebe-biopharma.org

The Biotechnologie-Industrie-Organisation Deutschland (BIO Deutschland) with offices in Berlin is the independent organisation for German biotechnology companies. The association is developing and supporting an innovative industry in Germany on the basis of modern life sciences. Founded in October 2004, BIO Deutschland currently has more than 230 member companies. To support its members BIO Deutschland is active on a wide range of measures like lobbying, public relations, or offering business development opportunities. BIO Deutschland is governed by a Board of Directors made up of 10 CEOs, CFOs and Managing Directors of companies that represents widely the German biotech sector.

BIO Deutschland
 Tegeler Weg 33 | berlinbiotechpark | 10589 Berlin | Germany
 Tel: +49 30 3450593-30 | Fax +49 30 3450593-59
 info@biodeutschland.org | www.biodeutschland.org

Platinum Sponsors

Bayerisches Staatsministerium für
 Wirtschaft, Infrastruktur, Verkehr und Technologie



Biotech Cluster
 Development

Gold Sponsor



Silver Sponsors



Conference Supporter



Media Partner



24–25 JUNE 2009 | MUNICH | GERMANY
Business Development Conference

Best Times for Good Deals?
 How Biotech and Pharma could partner now

In special partnership with



DAY ONE:

Wednesday, 24 June, 2009

10.30–11.00 Registration, Welcome Snack & Networking

11.00–11.15 Opening remarks by Peter Heinrich, member of the Board of BIO Deutschland and former member of the Board of EBE

11.15–11.45 **Keynote: Innovative financing pathways for biotechs facing heavy seas**

Siegfried Bialojan, Ernst & Young

11.45–12.45 Company Presentations

12.45–13.45 Light Buffet Lunch & Networking

13.45–15.15 Company Presentations

15.15–16.15 **Are niche markets the guarantee for future success? The case of therapies for rare diseases**

Moderator: Horst Domdey, Bio^M

Theresa Heggie, Jerini/Shire
Jörg Landwehr, PharmaMar

16.15–16.45 Coffee Break & Networking

16.45–17.45 Company Presentations

17.45–19.15 **Panel Debate: Partnering for proof of concept or develop it yourself and sell late (or never)?**

Strong competition for innovative products let some pharmaceutical corporations look further upstream – threat or opportunity for biotechs?

Moderator: Jürgen Drews, author of “In Quest of Tomorrow’s Medicines”

Edwin Moses, Ablynx
Ilka Wicke, Boehringer Ingelheim
Olaf Koenig, Daiichi Sankyo
Olaf Wilhelm, Willex
Lucienne Cicurel, Debiopharm

20.00–22.30 Bavarian Evening, Networking and Dinner

Company Presentations:

Wednesday, 24 June, 2009

11.45–12.45 · BioTie Therapies Corp.
· SuppreMol GmbH
· Innovacel Biotechnologie AG
· Cevtec Pharmaceuticals GmbH

13.45–15.15 · Oryzon Genomics SA
· Revotar Biopharmaceuticals AG
· Immunocore Ltd.
· Caprotec Bioanalytics GmbH
· Meta-IQ ApS
· Protagen AG

16.45–17.45 · Apogenix GmbH
· Debiopharm SA
· Cellca GmbH

Company Presentations:

Thursday, 25 June, 2009

10.00–11.00 · Vivia Biotech SL
· KeyNeurotek Pharmaceuticals AG
· Agenolab GmbH & Co. KG
· MorphoSys AG

DAY TWO:

Thursday, 25 June, 2009

09.00–09.30 Welcome Coffee & Networking

09.30–10.00 **Keynote: Impact of the global financial crisis on the biopharmaceutical sector – How to position your company**

Jörg Neermann, Life Sciences Partners

10.00–11.00 Company Presentations

11.00–11.30 Coffee Break & Networking

11.30–13.00 **Panel Debate: Too small to be seen by the industry giants? How Europe’s biotech companies can attract more attention**

Are public companies the winners? Differences between public and private companies competing for attraction?

Moderator: Emmanuel Chantelot, EBE

Lubor Gaal, Bristol-Myers-Squibb
Jörn-Peter Halle, Merck-Serono
Graziano Seghezzi, Sofinova Partners
Hans Christinger, Roche

13.00–13.15 Closing remarks by ASEBIO

13.15–14.15 Buffet Lunch, Networking and Departure